Clinical trials: Chronic Nephropathy
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Hyperparathyroidism, Chronic Kidney Disease
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease.
- Trial name
- NCT01191762
- Testing
- sevelamer carbonate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kenneth R. Phelps, M.D.
End Stage Renal Disease
A Research Study for Patients With End-Stage Renal Disease (ESRD)
The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.
- Trial name
- NCT00110890
- Testing
- cinacalcet, Standard of care
- Volunteers
- 552 people
- Sponsor
- Amgen
End Stage Renal Disease
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm.
- Trial name
- NCT01395823
- Testing
- ergocalciferol supplementation
- Where
- 12 sites in United States
- Volunteers
- 470 people
- Sponsor
- Dialysis Clinic, Inc.
Renal Failure, End Stage Renal Disease
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Trial name
- NCT02644941
- Testing
- Human Acellular Vessel (HAV), ePTFE graft
- Where
- 38 sites in United States, Germany and 4 more
- Volunteers
- 355 people
- Sponsor
- Humacyte, Inc.
Uremic Pruritus
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- NCT03422653
- Testing
- CR845 0.5 mcg/kg
- Where
- 57 sites in United States
- Volunteers
- 378 people
- Sponsor
- Cara Therapeutics, Inc.
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD4 (NCT03242018)
- Testing
- Sotagliflozin
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 277 people
- Sponsor
- Lexicon Pharmaceuticals
FSGS
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
- Trial name
- NCT02683889
- Testing
- Acthar
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Colorado, Denver
Chronic Kidney Diseases
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
Chronic kidney disease (CKD) is a burden of morbidity and mortality. Increased protein breakdown in skeletal muscle (wasting) and ectopic fat deposition are important determinants of poor clinical outcome in patient with CKD.
- Trial name
- GLIMP (NCT05254418)
- Testing
- dulaglutide injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
End-stage Renal Disease
Vitamin D and Arteriovenous Fistulae
Patients requiring hemodialysis following kidney failure need a form of dialysis vascular access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an enormous clinical problem.
- Trial name
- NCT00912782
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Emory University
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Heart Failure
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.
- Trial name
- NCT01598740
- Testing
- CLP, Spironolactone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sorbent Therapeutics
Renal Insufficiency, Chronic
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
This study aims to demonstrate the possible benefit of a treatment based on double diuretic in patients with chronic kidney disease and severely impaired glomerular filtration rate.
- Trial name
- NCT03923933
- Testing
- Chlorthalidone, Bumetanide
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Kidney Disease, Kidney Failure, Chronic
Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
The purpose of this study is to evaluate the effect of a short-term aliskiren treatment on kidney metabolism in patients at high risk for developing kidney dysfunction (i.e. kidney transplanted patients).
- Trial name
- NCT01437943
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)
The aims of this post-marketing observational study (PMOS) are to evaluate the time period needed to achieve > 30% decrease of intact parathyroid hormone (iPTH) compared to the initial values and to provide data on the…
- Trial name
- NCT01224782
- Where
- 69 sites in Bulgaria, Czechia and 1 more
- Volunteers
- 994 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases
A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)
This multi-center, randomized, double-blind, placebo-controlled, Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with CKD due to multiple etiologies at risk of rapid…
- Trial name
- MERLIN (NCT04702997)
- Testing
- Bardoxolone methyl oral capsule
- Where
- 12 sites in United States
- Volunteers
- 81 people
- Sponsor
- Biogen
Chronic Kidney Disease
Study to Evaluate the Prospective Payment System
To describe trends in treatment patterns of Small Dialysis Organizations (SDOs) prior to and during the implementation of the Centers for Medicare and Medicaid Services' (CMS') policy [End Stage Renal Disease (ESRD) Prospective…
- Trial name
- STEPPS™ (NCT01717989)
- Where
- 41 sites in United States, Puerto Rico
- Volunteers
- 2,248 people
- Sponsor
- Amgen
Iron Deficiency Anaemia, Iron Deficiency Anemia
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
- Trial name
- NCT02940860
- Testing
- Iron isomaltoside/ferric derisomaltose, Iron sucrose
- Where
- 141 sites in United States
- Volunteers
- 1,538 people
- Sponsor
- Pharmacosmos A/S
Kidney Transplantation, Chronic Kidney Failure
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney…
- Trial name
- BENEFIT (NCT00256750)
- Testing
- Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
- Where
- 105 sites in United States, Argentina and 19 more
- Volunteers
- 738 people
- Sponsor
- Bristol-Myers Squibb